what is a glp 1 drug made from America's Poison Centers Weight loss with GLP-1 medicines

See Figure 2: Systemic Effects of GLP-1 agonist Medications

The ECD was reported to be relatively dynamic even in the presence of hormone peptide

Efficacy and Safety of Efpeglenatide in Patients with Type 2 Diabetes and Obesity: a Systematic Review

Studies such as the LEADER trial (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown reductions in major adverse cardiovascular events, including heart attack and stroke, in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk

In general, since many patients already pay out-of-pocket for GLP-1 drugs, tariff-induced price increases would directly impact affordability and access, potentially limiting the availability of these therapies